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Endotoxin, also known as lipopolysaccharide (LPS) produced by bacteria can be present in any liquid or
on any biomaterial even if the material is sterile. Endotoxin in mammals can cause fever, inﬂammation,
cell and tissue damage and irreversible septic shock and death. In the body, endothelial cells making up
the blood vasculature and endothelial cells in vitro rapidly react to minute amounts of endotoxin
resulting in a rapid induction of the cell adhesion molecule E-selectin. In this study we have used
immunoﬂuorescent staining to evaluate the expression of E-selectin on human microvascular endo-
thelial cells from the skin (HDMEC) and human umbilical vein endothelial cells (HUVEC) exposed to
various concentrations of LPS. In addition, the sensitivity of detection was compared with the most
widely used assay for the presence of endotoxin, the Limulus Amebocyte Lysate assay (LAL). The
detection of E-selectin on endothelial cells in the presence of LPS for 4 h was found to be at least as
sensitive in detecting the same concentration using the LAL assay. A cell adhesion molecule-enzyme
immunosorbent assay was also developed and used to quantify LPS using the endothelial cell model.
A comparison of LAL and the immunoﬂuorescent staining method was carried out with solutions,
nanoparticles, biomaterial extracts and endothelial cells grown directly on biomaterials. Under all con-
ditions, the endothelial/E-selectin model system was positive for the test samples that were positive by
LAL. Thus, we propose the use of this highly sensitive, rapid, reproducible assay for the routine testing of
endotoxin in all steps in the manufacturing process of materials destined for use in humans. This can give
a rapid feedback and localization of bacterial contamination sources with the LAL being reserved for the
testing of the ﬁnal product.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Biomedical manufacturers and scientists are increasingly
developing compounds and materials for applications in the hu-
man body. These range from large-sized biomaterials for tissue
engineering and regeneration to ultra-small nanoparticles for
delivering active compounds into and to speciﬁc targets in the
body. Thesematerials are often extracted or processed from natural
compounds or synthesized in laboratories and involve numerous
steps in the manufacturing process, in which solutions, solvents or
other compounds are added. Prior to their use in humans, these.
r Ltd. Open access under CC BY-NC-NDmaterials go through extensive evaluation in in vitro studies, fol-
lowed by animal studies and ﬁnally pre-clinical studies. The man-
ufactured compounds must not only demonstrate their
functionality and biocompatibility for their desired target of inter-
est, theymust also be sterile, exhibit no undesirable side effects and
be free of endotoxin [1].
Endotoxin or bacterial lipopolysaccharide (LPS) (the terms are
synonymous) is practically ubiquitous. LPS is part of the outer
membrane of gram-negative bacteria [2]. Bacterial cells only
secrete small amounts of LPS during replication, however, sub-
stantial amounts may be released during the destruction of the
cells by antibiotics or host immune cells, by killing and rupturing
bacteria through heating solutions containing bacteria or adding
solvents [3]. Unfortunately, endotoxin is very stable and is highly
resistant to destruction by high temperatures or non-neutral pH
values compared to other compounds [4]. In addition, endotoxin
can adhere strongly to many materials and once present is difﬁcult
if not impossible to remove completely [5]. Themajor problemwith license.
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vator of a number of cell types in the body such as leukocytes,
platelets, endothelial, epithelial and dendritic cells, as well as cells
of the monocyte-macrophage lineage. When even a small amount
of endotoxin (1 ng) gains access to the bloodstream this can result
in fever and shivering, and, in larger amounts, to systemic inﬂam-
mation, cell and tissue damage, adult respiratory distress syndrome
and even irreversible septic shock and death [6,7].
Endotoxin can be detected by a number of methods. The rabbit
pyrogen testwas the ﬁrst assay developed to test solutions destined
for injection into humans. This test is based on the ability of
endotoxin to cause fever in rabbits and is sensitive to 0.5 EU/ml (see
below). A more quantitative in vitro assay was developed in the
1970s using a lysate from horseshoe crab (Limulus polyphemus)
amebocytes that clots in the presence of very low levels of endo-
toxin [3]. This is the standard assay used today and the Limulus
Amebocyte Lysate (LAL) gel clot assay is highly sensitive and is able
to detect 0.03 Endotoxin Units (EU)/ml [3]. It is generally accepted
that one EU equals approximately 0.1e0.2 ng endotoxin/ml. More
sensitive LAL assays have been developed capable of detecting
0.001 EU/ml (100 fg/ml). The LAL test is the method of choice for
detection of endotoxin as set down by the US Food and Drug
Administration guidelines for medical devices and parenteral drugs
[8]. A colorimetric cell-based assay to detect LPS, particularly the
lipid A portion of LPS has also been developed and exhibits a
sensitivity as low as 0.3 ng/ml. Other methods have also been re-
ported but are not widely used. In all cases, test solutions are added
either directly to the endotoxin test systems or solutions are pre-
pared by immersing compounds in liquids for a minimal 1 h at
room temperature to release endotoxins and these are then added
to the test system.
Under pro-inﬂammatory conditions, such as in the presence of
interleukin 1 (IL-1), or tumor necrosis factor alpha (TNF-alpha), as
well as exposure to LPS, human endothelial cells in vitro and in vivo
rapidly induce the expression of the cell adhesion molecule E-
selectin (also known as leukocyte-endothelial cell adhesion mole-
cule 2 (LECAM2), CD62 antigen-like family member E (CD62E) or
endothelial-leukocyte adhesion molecule 1 (ELAM-1)) [9]. In both
cases, in the absence of endotoxin no expression of E-selectin is
present. Endothelial cells exposed to LPS exhibit high expression of
E-selectin within 4 h and this decreases slowly over 24 h. The
expression can easily be observed by immunological staining
methods.
In this study, this reproducible characteristic of endothelial
cells e the absence of E-selectin on normally growing cells and the
rapid induction of E-selectin on cells after exposure to endotoxin e
was used to determine whether this system could be used to
rapidly evaluate solutions and materials for the presence of endo-
toxin. Human endothelial cells were exposed to different LPS types
and concentrations andwere examined for expression of E-selectin,
this being compared to detection by LAL. Furthermore, a CAM-EIA
(cell adhesion molecule e enzyme immunosorbent assay) was
evaluated for quantifying the amounts of LPS in solution. Finally,
detection of E-selectin on endothelial cells on biomaterials or
exposed to nanoparticles or solutions with and without natural
endotoxin contamination were examined.
2. Materials and Methods
2.1. Cells
Human dermal microvascular endothelial cells (HDMEC) were isolated from
juvenile foreskin as previously described and cultured in Endothelial Basal Medium
MV (PromoCell) supplemented with 15% fetal bovine serum (Invitrogen), 100 U/
100 mg/ml Penicillin/Streptomycin (Invitrogen), sodium heparin (10 mg/ml) and basic
ﬁbroblast growth factor (bFGF, 2.5 ng/ml) [10]. HUVEC were isolated according to a
previously published method [11]. Cells were cultured in medium M199 (Sigmae
Aldrich, Steinbach, Germany) þ 20% FCS (Life Technologies, Karlsruhe,Germany) þ 2 mM Glutamax I (Life Technologies) þ 100 U/100 mg/ml Pen/
Strep þ 25 mg/ml sodium heparin (SigmaeAldrich) þ 25 mg/ml endothelial growth
factor supplement (ECGS, Becton Dickinson, Bedford, MA). Cells were used in the 3rd
or 4th passage.
2.2. LPS e endotoxin
LPS from Escherichia coli was obtained from Sigma and Lonza (E. coli O111:B4,
L2630). Serial dilutions were prepared in sterilewater (weight/ml). The LPS obtained
from Lonza was also the same LPS used in the LAL assay described below.
2.3. Immunoﬂuorescent staining method for detection of E-selectin
E-selectin expression on endothelial cells was visualized by immunoﬂuorescent
(IF) staining. After exposure to LPS or compounds of interest for a given time (4 h),
the cells were rinsed twice with PBS, ﬁxed in 3.7% paraformaldehyde for 15 min,
permeabilized in 0.2% (v/v) buffered Triton X-100 for 10 min, and then incubated in
1% bovine serum albumin (BSA)/PBS) for 1 h. Cells were subsequently incubated
with mouse anti-human CD-31 (M0823 Dako, diluted 1:50 in 1% BSA/PBS) for 1 h,
washed 3X with PBS and then incubated with anti-mouse Alexa Fluor 488-
conjugates (or similar, Molecular Probes) diluted 1:1000 in 1% BSA/PBS for
60 min. Cell nuclei were counterstained with Hoechst 33342 (Molecular Probes)
diluted in PBS (0.5 mg/mL) for 10 min or with DAPI [12]. The samples were mounted
with Gel/Mount (Biomeda) and observed in a ﬂuorescent microscope or by confocal
laser scanning microscopy (CLSM). Negative controls were performed by omitting
the primary antibodies. For all studies, endothelial cells without LPS and with 1 mg/
ml LPS were used as negative (basal level E-selectin expression) and positive con-
trols, respectively.
2.4. CAM-EIA for E-selectin
A cell adhesion molecule e enzyme immunoassay (CAM-EIA) previously
described was used to analyze the amounts of E-selectin induced by test compounds
(LPS or solutions and materials) on endothelial cells [13]. Cells were seeded on a 96-
Ewell plate (15,000 cells/well), coated with ﬁbronectin (5 mg/ml). After 24 h, me-
dium was removed from the wells and fresh media added which contained various
dilutions of test solutions. At least 3 wells were used per sample. After 4 h at 37 C,
medium was removed and cells were washed with PBS. PBS was removed and cells
were ﬁxed with methanol/ethanol (2:1) at RT for 15 min. After this, wells were
washed 2Xwith PBS (at this point plates can be stored at 4 C until further analyzed).
PBS was removed, and 100 ml of a 1:10 dilution of blocking reagent with 1% H2O2
(blocking reagent for ELISA, Roche) was added to each well and incubated at 37 C
for 30 min. Subsequently, the reagent was decanted and 50 ml of primary antibody
(E-selectin, 1:2000 Bender MedSystems Cat. BMS110 in blocking reagent) was added
to each well and incubated at 37 C for 45 min. Wells were then rinsed 3X with PBS
prior to the addition of 50 ml of secondary antibody (1:1000 dilution of IgG bio-
tinylated goat anti-mouse, GE Healthcare Cat. RPN1177V) followed by an incubation
for 45min at 37 C. After this, wells were again rinsed 3Xwith PBS and after the ﬁnal
rinse, 100 ml of streptavidin-biotinylated horseradish peroxidase complex (GE
Healthcare Cat. RPN1051V) was added and incubated 1hr at 37 C. This was followed
by washing 6X with PBS. Finally, 170 ml of freshly prepared o-phenylenediamine
dihydrochloride substrate was added (Sigma Cat. P7288, 20 mg tablet in phosphate-
citrate buffer with H2O2, prepared according to manufacturer’s instructions). After
20min at 37 C,160 ml was removed from each well and added to 50 ml of 3M HCL in a
96 well plate. Absorption of the samples was then measured at 492 nm.
2.5. Limulus Amebocyte Lysate assay
The Limulus Amebocyte Lysate (LAL) was used as a quantitative test for LPS and
was carried out according to themanufacturer’s protocol (Limulus Amebocyte Lysate,
QCL-1000, Lonza). Brieﬂy, 50 ml of test sample were added to the test well in the 96-
well plate at 37 C. At least 3 wells were used for each sample. The linearity of the
standard was veriﬁed using LPS supplied in the kit. At T¼ 0, 50 ml of LAL was added to
each well. At T¼ 10 min, 100 ml of substrate solutionwas added. At T¼ 16min,100 ml
of stop reagent was added. After this absorbance was read at 405e410 nm.
2.6. Conditions for the evaluation of the presence of endotoxin on solids and in
liquids
To determine the expression of E-selectin on endothelial cells exposed to
different types of biomaterials or other compounds or solutions, various methods
were used. For studies of solutions (such as water, stock solutions or buffers, etc.,
nanoparticles or other granulate containing solutions or similar mixtures), cells
were grown in Lab-Tek II Chamber Slides coated with ﬁbronectin (5 mg/ml),
cultured until nearly conﬂuent and then the solutions were added. After 4 h, the
solutions were removed and cells werewashed 2e3 times with PBS. For studies of 3-
D materials three different approaches could be used. The ﬁrst is similar to that
recommended for the LAL assay: materials were incubated overnight in cell culture
media after which the media was removed and added to cells growing in Chamber
slides (as described above, also know as extraction or leaching experiment). In the
other twomethods, cells were either added onto and grown directly on thematerial,
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removed after 4 h. If the chamber slides were too small to hold the test material, cell
numbers were scaled up for growth in 35 mm petri plates. As in chamber slide
studies, cells were incubated for 4 h in the presence of the test material and then
washed 3X with PBS before proceeding with the IF staining protocol for detection of
E-selectin expression (described above). To evaluate the expression and staining
pattern of E-selectin on the particular donor of endothelial cells either exposed to
solutions or growing on different materials, controls with cells incubated with and
without 1 mg/ml LPS for 4 h were carried out.3. Results
HUVEC or HDMEC exposed to 1 mg/ml of LPS for 4 h exhibited a
strong, nearly 100% staining for E-selectin (Fig. 1b and d, respec-
tively) whereas, little to no expression was observed on HUVEC or
HDMEC in the absence of LPS (Fig. 1a and c, respectively. An ex-
amination of E-selectin in at least 50 different donors for HUVEC
and HDMEC demonstrated a similar staining pattern.
To determine the minimum concentration at which cells
showed a detectable induction for E-selectin, serial dilutions of LPS
were prepared and cells were treated for 4 h with the various di-
lutions (in chamber slides). After this, cells were ﬁxed and stained
for the expression of E-selectin as described in Materials and
Methods and then examined using a standard immunoﬂuorescent
or confocal microscope. A representative staining pattern of a
dilution series of LPS concentrations for HUVEC can be seen in
Fig. 2A and 10 higher magniﬁcation in Fig. 2B of the respective
images from Fig. 2A. At concentrations of LPS between ranging from
1 mg/ml to 1 ng/ml, the E-selectin staining pattern was similar with
a cap of staining on one side of the nuclei and a diffusion of stain
into the cytoplasm. At lower concentrations, the cytoplasmic
staining decreased, as well as the number of cells staining posi-
tively, however, the staining still remained associated with the
nuclei and at one location in the peri-nuclear region. At very high
dilutions, E-selectin expression could still be observed as a small
elongated spot closely associated to one location on the nuclearFig. 1. E-selectin staining on HUVEC and HDMEC in the presence and absence of LPS. HUVEC
the absence (a, c) or presence of 1 mg/ml LPS (b, d). Nuclei were stained with Dapi (blue).periphery (see arrows and higher magniﬁcation in Fig. 2B). The
sensitivity of E-selectin detection by immunoﬂuorescent staining in
three different donors of HUVEC or HDMEC was found to be be-
tween 1 and 100 fg/ml (data not shown).
A CAM-EIA E-selectin assay was previously developed and
described to examine and follow the induction of this cell adhesion
molecule on endothelial cells after exposure to external stimuli,
such as pro-inﬂammatory markers, etc. [13]. This CAM-EIA was
used to evaluate the sensitivity of detection of various concentra-
tions of LPS. As can be seen in Fig. 3, the system could routinely
detect concentrations of LPS in solution as low as 100 fg/ml and in
many cases lower (data not shown).
To compare the sensitivity of endothelial cells to LPS with
other methods used to detect LPS/endotoxin we analyzed the LPS
dilutions from the CAM-EIA assay above in the most commonly
used in vitro system for endotoxin detection and quantiﬁcation,
the LAL assay system (Fig. 4). As can be seen in Fig. 4, the assay
was capable of detecting the LPS in the serial dilutions to a
concentration of approximately 10 pg/ml. These results were
observed for both sources of LPS examined. The detection limit
with the LAL assay was 2 magnitudes of sensitivity less than the
routinely observed detection limit of the endothelial cells in the
CAM-EIA. In addition, the LAL assay appears to be less able to
discriminate between higher concentrations of LPS (1 mg, 100 ng,
10 ng, 1 ng).
Cells growing on or exposed to various types of biomaterials
were examined for E-selectin staining and compared to results
obtained by LAL testing. Fig. 5 shows the results obtained in the
analysis of gelatin nanoparticles, solutions used to prepare the
gelatin nanoparticle suspension (a-f) and cells growing on or next
to a bone biomaterial scaffold (g-j). The results obtained by LAL
are listed directly in the images. As can be seen in Fig. 5a, the
gelatin NPs were positive for endotoxin as determined by LAL and
the cells exposed to the gelatin NPs stained positive for E-selec-
tin. The buffer used to resuspend the gelatin NPs supplied by the(a and b) and HDMEC (c and d) stained for the presence of E-selectin (green) after 4 h in
Fig. 2. Images of HUVEC grown in chamber slides and exposed to decreasing concentrations of LPS and stained for E-selectin (green) and nuclei (blue). Arrows at lower con-
centration of LPS show positive cells. A are images of HUVEC exposed to serially diluted LPS at the indicated concentration per ml. B are selective respective images from A at the
concentration indicated at a higher magniﬁcation. Arrows in the images of cells exposed to the lower concentrations in B demonstrate the nuclear capped location of E-selectin
expression. Similar results were observed with multiple donors of HUVEC and HDMEC.
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Fig. 3. Detection of serial dilutions of LPS shown in Fig. 2 as detected in the E-selectin CAM-EIA. The data is from one donor each of HUVEC and HDMEC. Similar results were
observed by at least 2 further donors of each cell type.
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exposed to the buffer stained positive for E-selectin (b). A further
analysis of the ultrapuriﬁed and then sterilized water used to
prepare the buffer also obtained from the manufacturer indicated
that the ﬁltered water was a source of the endotoxin. This water
was LAL positive and after adding the water to endothelial cells,
E-selectin was induced (c). Finally, when the synthesized gelatin
NPs were resuspended in endotoxin-free buffer, no induction of
E-selectin was observed and the NPs were LAL negative (d). This
indicated that the original source of water, even though sterilized
was the source of endotoxin. Fig. 5e and f, are the negative and
positive controls, respectively. An examination of the expression
of E-selectin of endothelial cells on a bone biomaterial is seen in
Fig. 5, gej. HDMEC cells grown on a biomaterial or next to aFig. 4. Detection of serial dilutions of LPSbiomaterial were evaluated for E-selectin induction. The material
was based on hydroxyapatite and the surface was modiﬁed with a
coating of collagen. The material was found to contain endotoxin
by LAL staining. As can be seen in (g), HDMEC (stained with
calcein AM) readily grew on the material. E-selectin staining of
the cells on the material showed positive cells (Fig. 5, h). The
same biomaterial was added to a well of HDMEC cells growing in
a monolayer. After 4 h exposure, the material was removed and
the cells were stained for E-selectin. As can be seen in Fig. 5, i, the
endothelial cells stained positively for E-selectin. Cells not
exposed to the material were negative for E-selectin (Fig. 5, j).
The results of the E-selectin staining completely overlap with the
results obtained by LAL. We have used this method to routinely
examine over 200 different suspensions of NPs and over 100shown in Fig. 2 as detected by LAL.
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itive samples were found to be negative by LAL (<10, data not
shown). Studies are underway to determine the cause of the
differences.
4. Discussion
An evaluation of E-selectin adhesion molecule expression in
response to endotoxin on primary human endothelial cells has
shown that this method is as sensitive as the currently, widely used
LAL assay for the detection of endotoxin in solutions and on solids
destined for use in humans. The detection of E-selectin on freshly
isolated HUVEC or HDMEC using immunoﬂuorescent staining or
quantiﬁcation with a CAM-EIA-based assay system is rapid and
easily done using equipment readily available in most cell biolog-
ical laboratories that also carry out LAL assays. Endothelial cells are
one of themajor cell types directly affected by endotoxin in vivo and
they participate in the cascade of reactions that result in important
pathological conditions in humans, such as sepsis. Therefore, using
human endothelial cells has a direct, biologically relevant signiﬁ-
cance and advantage since at some point after administration of
any material into the human body the material will come intoFig. 5. Images of cells with and without biomaterials and controls stained for E-selectin. Im
suspension of gelatin-based nanoparticles and solutions used to prepare the suspension. The
HUVEC after 4 h exposure to a suspension of gelatin-NPs. b is an image of E-selectin stain
resuspend the gelatin-NPs after a ﬁnal drying step. c is an image of E-selectin staining of H
water source after autoclaving. d is an image of E-selectin staining of HUVEC exposed to g
controls (E-selectin e red, nuclei stained with DAPI). Images g, h are images of HDMEC grow
HDMEC stained with calcein-AM, h are cells on HAC stained for E-selectin, i is an image of H
and j is an image of the control HDMEC stained for E-selectin in a well without exposure tcontact either directly or indirectly with endothelial cells making
up the vasculature. Thus, we propose that the in vitro model for E-
selectin detection for endotoxin using endothelial cells can be used
as a fast and reliable method to pre-screen all individual materials
and solutions used in the synthesis steps in the manufacturing
process of biomaterials in order to rapidly detect sources of endo-
toxin or ensure that they are free of endotoxin, and to give feedback
to those involved in the manufacturing process.
The development and manufacture of biomaterials has
increased rapidly in recent years. Often the natural or synthetic
materials or solutions used in the manufacture are not evaluated
for their natural microbial ﬂora or for those introduced at any time
during the manufacturing process and which may end up in the
ﬁnal product. Endotoxin or LPS from gram-negative bacteria are
increasingly being reported in biomaterials such as medical de-
vices, scaffolds for tissue engineering or nanoparticles for drug
delivery, but unfortunately, in most cases, studies have not been
done to determine the source of the contamination [14e17]. To this
end a number of articles dealing with biomaterials have referred to
endotoxin as “the uninvited guest” or “the invisible companion”
[14,15]. These low amounts of endotoxin after implantation in
humans have been implicated in implant loosening [17e21]. Theage a-f are a series of images of HUVEC cells stained for E-selectin used in evaluating a
results of an LAL assay are shown in the images. a is an image of E-selectin staining of
ing of HUVEC exposed to the buffer supplied by the manufacturer that was used to
UVEC exposed to the water used to prepare the buffer obtained from a ultra-ﬁltration
elatin-NPs resuspended in endotoxin-free water. e and f are the negative and positive
ing on a hydroxyapatite/collagen (HAC) scaffold stained for E-selectin. g is an image of
DMEC stained for E-selectin after 4 h exposure to HAC placed in the well with the cells
o materials (hej, E-selectin e green, nuclei stained with propidium iodide).
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endotoxin in medical devices, medicines or biological products
(International Standards Organization) [1]. Unfortunately, as this
assay is not being used routinely to examine all steps in the
manufacturing process but generally only for the end product, this
does not identify the source of the endotoxin. In addition, studies
are increasingly showing that certain compounds may interfere
with or not be detected by the different LAL assays available. This is
the result of endotoxin either sticking to materials and not being
extracted into solution for use in the LAL, or, for example, in
nanoparticles interfering with spectrophotometric detection [22e
24]. Another assay based on TLR4 reporter cells has also been
shown to be useful in detecting endotoxin, although cytotoxic ef-
fects were observed with certain nanoparticles thus limiting the
measurements above particle toxicity [23]. Awhole-blood cytokine
release assay has also been used to evaluate endotoxins from a
number of bacterial species, but has not received much further
testing [25].
Endotoxin injected into mammals gives rise to fever, septic
shock and eventually death of the animal [26,27]. The immune
system is able to detect and react to concentrations of LPS less than
1 ng/ml [28]. This is the basis of the rabbit pyrogen test and involves
injecting compounds suspected of containing endotoxin into the
blood stream of rabbits and monitoring the rise in temperature of
the animals. Monocytes and macrophages as well as vascular
endothelial cells are among the ﬁrst cells that come into contact
with endotoxin and this results in the induction of inﬂammatory
mediators [29]. One of the ﬁrst events in vivo and in vitro after
exposure to endotoxin, or proinﬂammatory cytokines such as
interleukin-1 and tumor necrosis factor, is the rapid increase in the
adherence of polymorphonuclear leukocytes and monocytes to the
endothelial cells [30]. This very rapidly inducible endothelial-
leukocyte adhesion molecule on endothelial cells was initially
designated as ELAM-1 and is today known as E-selectin [9].
Furthermore, this characteristic of human endothelial cells has
been used to show that both scaffolding biomaterials for tissue
engineering and nanoparticles for use in humans have no direct
effect on the inﬂammatory reaction of endothelial cells and that
endothelial cells in the presence of the biomaterials or nano-
particles retain the capability to respond to endotoxin by demon-
strating the induction of E-selectin [31,32]. These are two
characteristics that have been widely used to evaluate the endo-
thelial cell-compatibility of biomaterials. The unexplainable in-
duction of E-selectin in certain samples and the identiﬁcation by
LAL that the samples were contaminated with endotoxin was the
basis for using this endothelial cell characteristic as an indicator of
endotoxin presence (data not shown).
The use of the detection of induction of E-selectin on primary
human endothelial cells as a method to evaluate samples for the
initial screening for presence of endotoxin in large numbers of
samples has a number of advantages over the LAL. Microvascular
endothelial cells are one of the major cell types that directly
respond to endotoxin in the body and endothelial cells at some
point will come into contact with the introduced material whether
it is implanted, injected, inhaled or swallowed. It is the biologically
relevant and most closely related cell equivalent to the rabbit py-
rogen assay. Furthermore, these human cells are readily available,
easily cultivated and the reagents for the detection of E-selectin are
relatively inexpensive compared to the relatively costly LAL assay,
which also requires the capturing of horeshoe crabs and removing
their blood. The equipment needed for human cells are similar to
those required for the LAL assay and are standard in most cell
biology laboratories. The assay for endotoxin can be conducted on
solutions directly added to the cells, with extracts prepared from
materials, with materials placed on cultured cells directly or oncells grown directly on the materials. Thus, the assay can readily be
scaled up tomeet the size of thematerial. Thus, we propose that the
assay be used to initially routinely screen all solutions and mate-
rials in all steps in the manufacturing process of biomaterials to
rapidly identify sources of endotoxin so that they can be removed
and replaced with the LAL assay being used only on ﬁnal materials
as required for certiﬁcation procedures.
5. Conclusion
An assay system has been described using human endothelial
cells that offers an alternativemethodwith similar sensitivity to the
commonly used LAL assay system to detect endotoxin. The E-
selectin assay uses methods and equipment similar to that found in
laboratories using the standard LAL assay. An E-selectin CAM-EIA
can also be used to quantify the amount of endotoxin present.
We propose that the human endothelial cell E-selectin induction
assay be used to follow all steps in the manufacturing process of
biomaterials to locate potential sources of contamination rapidly
and remove these from the process. A ﬁnal conﬁrmation prior to
administration of materials into humans or animals can then be
performed as is currently done using the accredited LAL assay.
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